We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Anticancer Therapies – Products


Tumor Exosomes: A Messenger for Cancer Progression

This whitepaper explores the role of extracellular vesicles in cell-to-cell communication during cancer progression. It also highlights a range of high-quality recombinant proteins, antibodies and cytokines and to support exosome research.

Cancer Drugs

How To Accelerate and De-Risk Drug Development in Oncology

Although there are initiatives to de-risk the drug development process, continually applying the same tools and approaches is unlikely to lead to innovative, first- or best-in-class targets and transformative progress.
Two medical professionals looking at a computer screen.
Product News

Oncodesign Services Announce Access to ImaginAb’s CD8 ImmunoPET™ Technology

Oncodesign Services announces the execution of a Preclinical License and Supply Agreement with ImaginAb Inc. for the use of their investigational CD8 ImmunoPET™ (89Zr crefmirlimab berdoxam) technology.
Cell and Gene Therapy Applications

Cell and Gene Therapies: Innovations and Applications

Cell and gene therapies seek to correct the root cause of an illness at the molecular level. These game-changing medicines are reshaping how we address previously untreatable illnesses – transforming people’s lives.
The Avacta logo
Product News

Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase I Clinical Study

Avacta Group plc has announced that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully.
Remegen logo.
Product News

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

RemeGen Co., Ltd announced the latest clinical research results on disitamab vedotin at this year's American Society of Clinical Oncology Annual Meeting.

SCF-c-Kit Signaling Axis: A Cancer Stemness Regulator

As a global leader in the recombinant technology, Sino Biological provides a diverse array of recombinant proteins, antibodies, and ELISA kits to facilitate research and development of cancer treatments that focus on c-Kit and other RTKs (EGFR, VEGFR, PDGFR, c-Met, TrkB, FGFR, and more).
Oncohost logo.
Product News

OncoHost To Present PROphet® Biomarker Model That Accurately Predicts Clinical Benefit to ICI-Based Treatment

OncoHost has announced that it will give a poster presentation demonstrating the accuracy of its PROphet® biomarker model at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023, in Chicago, Illinois.
The new M Bio building.
Product News

Cell and Gene Therapy CDMO Targets North American Growth With Major US Acquisition

uBriGene, a cell & gene therapy contract development and manufacturing organization, is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc.
T cells attacking a cancer cell.
Product News

Efficient Transduction of CAR Into T Cells

AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.